Search

Your search keyword '"Pressiani, Tiziana"' showing total 189 results
Start Over Author "Pressiani, Tiziana" Publication Year Range Last 3 years
189 results on '"Pressiani, Tiziana"'

1. Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib

Author

Stefanini, Bernardo, Tovoli, Francesco, Trevisani, Franco, Marseglia, Mariarosaria, Di Costanzo, Giovan Giuseppe, Cabibbo, Giuseppe, Sacco, Rodolfo, Pellizzaro, Filippo, Pressiani, Tiziana, Chen, Rusi, Ponziani, Francesca Romana, Foschi, Francesco Giuseppe, Magini, Giulia, Granito, Alessandro, and Piscaglia, Fabio

Published
2024
Full Text
View/download PDF

2. Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study

Author

Rimini, Margherita, Masi, Gianluca, Lonardi, Sara, Nichetti, Federico, Pressiani, Tiziana, Lavacchi, Daniele, Jessica, Lucchetti, Giordano, Guido, Scartozzi, Mario, Tamburini, Emiliano, Pastorino, Alessandro, Rapposelli, Ilario Giovanni, Daniele, Bruno, Martinelli, Erika, Garajova, Ingrid, Aprile, Giuseppe, Schirripa, Marta, Formica, Vincenzo, Salani, Francesca, Winchler, Costanza, Bergamo, Francesca, Balsano, Rita, Gusmaroli, Eleonora, Lorenzo, Angotti, Landriscina, Matteo, Pretta, Andrea, Toma, Ilaria, Pirrone, Chiara, Diana, Anna, Leone, Francesco, Brunetti, Oronzo, Brandi, Giovanni, Garattini, Silvio Ken, Satolli, Maria Antonietta, Rossari, Federico, Fornaro, Lorenzo, Niger, Monica, Zanuso, Valentina, De Rosa, Antonio, Ratti, Francesca, Aldrighetti, Luca, De Braud, Filippo, Foti, Silvia, Rizzato, Mario Domenico, Vivaldi, Caterina, Stefano, Cascinu, Rimassa, Lorenza, Antonuzzo, Lorenzo, and Casadei-Gardini, Andrea

Published
2024
Full Text
View/download PDF

3. Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab

Author

Rimini, Margherita, Loi, Eleonora, Rizzato, Mario Domenico, Pressiani, Tiziana, Vivaldi, Caterina, Gusmaroli, Eleonora, Antonuzzo, Lorenzo, Martinelli, Erika, Garajova, Ingrid, Giordano, Guido, Lucchetti, Jessica, Schirripa, Marta, Cornara, Noemi, Rossari, Federico, Vitiello, Francesco, Amadeo, Elisabeth, Persano, Mara, Piva, Vittoria Matilde, Balsano, Rita, Salani, Francesca, Pircher, Chiara, Cascinu, Stefano, Niger, Monica, Fornaro, Lorenzo, Rimassa, Lorenza, Lonardi, Sara, Scartozzi, Mario, Zavattari, Patrizia, and Casadei-Gardini, Andrea

Published
2024
Full Text
View/download PDF

5. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population

Author

Rimini, Margherita, Fornaro, Lorenzo, Rizzato, Mario Domenico, Antonuzzo, Lorenzo, Rossari, Federico, Satake, Tomoyuki, Vandeputte, Hanne, Vivaldi, Caterina, Pressiani, Tiziana, Lucchetti, Jessica, Kim, Jin Won, Abidoye, Oluseyi, Rapposelli, Ilario Giovanni, Tamberi, Stefano, Finkelmeier, Fabian, Giordano, Guido, Nichetti, Federico, Chon, Hong Jae, Braconi, Chiara, Pirrone, Chiara, Castet, Florian, Tamburini, Emiliano, Yoo, Changhoon, Parisi, Alessandro, Diana, Anna, Scartozzi, Mario, Prager, Gerald W., Avallone, Antonio, Schirripa, Marta, Kim, Il Hwan, Perkhofer, Lukas, Oneda, Ester, Verrico, Monica, Adeva, Jorge, Chan, Stephen L., Spinelli, Gian Paolo, Personeni, Nicola, Garajova, Ingrid, Rodriquenz, Maria Grazia, Leo, Silvana, Salani, Francesca, De Rosa, Antonio, Lavacchi, Daniele, Foti, Silvia, Ikeda, Masafumi, Dekervel, Jeroen, Niger, Monica, Balsano, Rita, Tonini, Giuseppe, Kang, Minsu, Bekaii-Saab, Tanios, Esposito, Luca, Boccaccino, Alessandra, Himmelsbach, Vera, Landriscina, Matteo, Djaballah, Selma Ahcene, Zanuso, Valentina, Masi, Gianluca, Lonardi, Sara, Rimassa, Lorenza, and Casadei-Gardini, Andrea

Published
2024
Full Text
View/download PDF

6. Multicenter phase I/II trial of gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer

Author

Pressiani, Tiziana, Balsano, Rita, Giordano, Laura, Milella, Michele, Bergamo, Francesca, Bozzarelli, Silvia, Noventa, Silvia, Ferrrari, Daris, Scartozzi, Mario, Parra, Hector Soto, Auriemma, Alessandra, Soldà, Caterina, Zaniboni, Alberto, Zecchetto, Camilla, Rizzato, Mario Domenico, Rimassa, Lorenza, and Santoro, Armando

Published
2024
Full Text
View/download PDF

7. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

Author

Vithayathil, Mathew, D’Alessio, Antonio, Fulgenzi, Claudia Angela Maria, Nishida, Naoshi, Schönlein, Martin, von Felden, Johann, Schulze, Kornelius, Wege, Henning, Saeed, Anwaar, Wietharn, Brooke, Hildebrand, Hannah, Wu, Linda, Ang, Celina, Marron, Thomas U., Weinmann, Arndt, Galle, Peter R., Bettinger, Dominik, Bengsch, Bertram, Vogel, Arndt, Balcar, Lorenz, Scheiner, Bernhard, Lee, Pei-Chang, Huang, Yi-Hsiang, Amara, Suneetha, Muzaffar, Mahvish, Naqash, Abdul Rafeh, Cammarota, Antonella, Zanuso, Valentina, Pressiani, Tiziana, Pinter, Matthias, Cortellini, Alessio, Kudo, Masatoshi, Rimassa, Lorenza, Pinato, David J., and Sharma, Rohini

Published
2023
Full Text
View/download PDF

8. Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

Author

Persano, Mara, Rimini, Margherita, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Rimassa, Lorenza, Presa, José, Masi, Gianluca, Yoo, Changhoon, Lonardi, Sara, Tovoli, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Pressiani, Tiziana, Kawaguchi, Takumi, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Piscaglia, Fabio, Hiraoka, Atsushi, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Iavarone, Massimo, Di Costanzo, Giovanni, Marra, Fabio, Scartozzi, Mario, Tamburini, Emiliano, Cabibbo, Giuseppe, Foschi, Francesco Giuseppe, Silletta, Marianna, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Cammarota, Antonella, Burgio, Valentina, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2023
Full Text
View/download PDF

9. A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma

Author

Balcar, Lorenz, Scheiner, Bernhard, Fulgenzi, Claudia Angela Maria, D’Alessio, Antonio, Pomej, Katharina, Roig, Marta Bofill, Meyer, Elias Laurin, Che, Jaekyung, Nishida, Naoshi, Lee, Pei-Chang, Wu, Linda, Ang, Celina, Krall, Anja, Saeed, Anwaar, Stefanini, Bernardo, Cammarota, Antonella, Pressiani, Tiziana, Abugabal, Yehia I., Chamseddine, Shadi, Wietharn, Brooke, Parisi, Alessandro, Huang, Yi-Hsiang, Phen, Samuel, Vivaldi, Caterina, Salani, Francesca, Masi, Gianluca, Bettinger, Dominik, Vogel, Arndt, von Felden, Johann, Schulze, Kornelius, Silletta, Marianna, Trauner, Michael, Samson, Adel, Wege, Henning, Piscaglia, Fabio, Galle, Peter R., Stauber, Rudolf, Kudo, Masatoshi, Singal, Amit G., Itani, Aleena, Ulahannan, Susanna V., Parikh, Neehar D., Cortellini, Alessio, Kaseb, Ahmed, Rimassa, Lorenza, Chon, Hong Jae, Pinato, David J., and Pinter, Matthias

Published
2024
Full Text
View/download PDF

10. Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?

Author

Rimini, Margherita, Persano, Mara, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Masi, Gianluca, Yoo, Changhoon, Lonardi, Sara, Piscaglia, Fabio, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Pressiani, Tiziana, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Hiraoka, Atsushi, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Burgio, Valentina, Rimassa, Lorenza, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2023
Full Text
View/download PDF

11. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

Author

Casadei-Gardini, Andrea, Rimini, Margherita, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Rimassa, Lorenza, Presa, José, Masi, Gianluca, Yoo, Changhoon, Lonardi, Sara, Tovoli, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Pressiani, Tiziana, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Piscaglia, Fabio, Hiraoka, Atsushi, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Iavarone, Massimo, Di Costanzo, Giovanni, Marra, Fabio, Scartozzi, Mario, Tamburini, Emiliano, Cabibbo, Giuseppe, Foschi, Francesco Giuseppe, Silletta, Marianna, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Burgio, Valentina, Persano, Mara, Della Corte, Angelo, Ratti, Francesca, De Cobelli, Francesco, Aldrighetti, Luca, Cascinu, Stefano, and Cucchetti, Alessandro

Published
2023
Full Text
View/download PDF

12. Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma

Author

Scheiner, Bernhard, Roessler, Daniel, Phen, Samuel, Lim, Mir, Pomej, Katharina, Pressiani, Tiziana, Cammarota, Antonella, Fründt, Thorben W., von Felden, Johann, Schulze, Kornelius, Himmelsbach, Vera, Finkelmeier, Fabian, Deibel, Ansgar, Siebenhüner, Alexander R., Shmanko, Kateryna, Radu, Pompilia, Schwacha-Eipper, Birgit, Ebert, Matthias P., Teufel, Andreas, Djanani, Angela, Hucke, Florian, Balcar, Lorenz, Philipp, Alexander B., Hsiehchen, David, Venerito, Marino, Sinner, Friedrich, Trauner, Michael, D'Alessio, Antonio, Fulgenzi, Claudia A.M., Pinato, David J., Peck-Radosavljevic, Markus, Dufour, Jean-François, Weinmann, Arndt, Kremer, Andreas E., Singal, Amit G., De Toni, Enrico N., Rimassa, Lorenza, and Pinter, Matthias

Published
2023
Full Text
View/download PDF

13. THU-464 aMAP score predicts progression-free survival in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

Author

Vithayathil, Mathew, primary, D'Alessio, Antonio, additional, Fulgenzi, Claudia, additional, Celsa, Ciro, additional, Manfredi, Giulia, additional, Nishida, Naoshi, additional, Schoenlein, Martin, additional, von Felden, Johann, additional, Schulze, Kornelius, additional, Wege, Henning, additional, Saeed, Anwaar, additional, Wietharn, Brooke, additional, Hildebrand, Hannah, additional, Wu, Linda, additional, Ang, Celina, additional, Marron, Thomas U., additional, Weinmann, Arndt, additional, Galle, Peter R., additional, Bettinger, Dominik, additional, Lin, Chun-yen, additional, Vogel, Arndt, additional, Scheiner, Bernhard, additional, Lee, Pei-Chang, additional, Huang, Yi-Hsiang, additional, Amara, Suneetha, additional, Muzaffar, Mahvish, additional, Naqash, Abdul Rafeh, additional, Zanuso, Valentina, additional, Pressiani, Tiziana, additional, Cabibbo, Giuseppe, additional, Dalbeni, Andrea, additional, Pinter, Matthias, additional, Singal, Amit, additional, Chon, Hong Jae, additional, Cortellini, Alessio, additional, Kudo, Masatoshi, additional, Rimassa, Lorenza, additional, Pinato, David J., additional, and Sharma, Rohini, additional

Published
2024
Full Text
View/download PDF

16. THU-446 VETC predicts benefit of anti-angiogenic drugs in advanced HCC

Author

De Carlo, Camilla, primary, Akpinar, Reha, additional, Durante, Barbara, additional, Pirozzi, Angelo, additional, Renne, Salvatore, additional, Pressiani, Tiziana, additional, Calderaro, Julien, additional, Zanuso, Valentina, additional, Ng, Irene Oi-Lin, additional, Cheung, Tanto, additional, Eccher, Albino, additional, Sighinolfi, Pamela, additional, Villa, Erica, additional, Iavarone, Massimo, additional, Maggioni, Marco, additional, Shao, Yu-Yun, additional, Lonardi, Sara, additional, Rizzato, Mario Domenico, additional, De Rosa, Antonio, additional, Fassan, Matteo, additional, Angerilli, Valentina, additional, Pedica, Federica, additional, Rimini, Margherita, additional, Giardini, Andrea Casadei, additional, Santoro, Armando, additional, Park, Young Nyun, additional, Roncalli, Massimo, additional, Terracciano, Luigi, additional, Piscuoglio, Salvatore, additional, Rimassa, Lorenza, additional, and Tommaso, Luca Di, additional

Published
2024
Full Text
View/download PDF

17. Repeated Previous Transarterial Treatments Negatively Affect Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib.

Author

Stefanini, Bernardo, Ielasi, Luca, Casadei-Gardini, Andrea, Piscopo, Michele, Tortora, Raffaella, Lani, Lorenzo, Pressiani, Tiziana, Sansone, Vito, Sacco, Rodolfo, Magini, Giulia, Renzulli, Matteo, Foschi, Francesco Giuseppe, Piscaglia, Fabio, Tovoli, Francesco, and Granito, Alessandro

Subjects
PROPENSITY score matching, HEPATOCELLULAR carcinoma, LIVER failure, OVERALL survival, SORAFENIB
Abstract

Background: Transarterial chemoembolisation (TACE) and radioembolisation (TARE) can lead to the deterioration of liver function, especially in cases of a high tumour burden, potentially lessening the benefits of subsequent systemic treatments. We aimed to verify whether a high number of previous transarterial treatments modified the outcomes of patients who received sorafenib as a frontline systemic treatment. Methods: A retrospective analysis of a large multicenter dataset containing prospectively collected data of sorafenib-treated patients was conducted. Results: Data from 696 patients were analysed, with 139 patients having received >two transarterial procedures before starting sorafenib. A propensity score matched 139 identified pairs of patients. Having received >two locoregional treatments was independently associated with a shorter survival (hazard ratio 1.325, 95% confidence interval 1.018–1.725, p = 0.039). This pattern was confirmed amongst responders to sorafenib, but not in progressors. A trend toward a higher rate of the permanent discontinuation of sorafenib due to liver failure (18.7 vs. 10.8%, p = 0.089) and a lower rate of eligibility for second-line treatments (24.5 vs. 17.3%, p = 0.184) was observed in patients who had received >two transarterial procedures. Conclusions: Repeated endovascular treatments negatively impacted the survival of HCC patients, especially sorafenib-responders. An early switch to systemic therapies should be considered in cases that are unlikely to respond. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction.

Author

Fulgenzi, Claudia Angela Maria, Scheiner, Bernhard, D'Alessio, Antonio, Mehan, Aman, Manfredi, Giulia F., Celsa, Ciro, Nishida, Naoshi, Ang, Celina, Marron, Thomas U., Wu, Linda, Saeed, Anwaar, Wietharn, Brooke, Cammarota, Antonella, Pressiani, Tiziana, Pinter, Matthias, Sharma, Rohini, Cheon, Jaekyung, Huang, Yi-Hsiang, Lee, Pei-Chang, and Phen, Samuel

Published
2024
Full Text
View/download PDF

19. Atezolizumab plus chemotherapy with or without bevacizumab in advanced biliary tract cancer: Results from a randomized proof-of-concept phase II trial (IMbrave151).

Author

El-Khoueiry, Anthony B., primary, Ren, Zhenggang, additional, Chon, Hong Jae, additional, Park, Joon Oh, additional, Kim, Jin Won, additional, Pressiani, Tiziana, additional, Li, Daneng, additional, Zhukova, Lyudmila, additional, Zhu, Andrew X., additional, Chen, Ming-Huang, additional, Hack, Stephen Paul, additional, Wu, Stephanie, additional, Liu, Bo, additional, Guan, Xiangnan, additional, Lu, Shan, additional, Wang, Yulei, additional, and Macarulla, Teresa, additional

Published
2024
Full Text
View/download PDF

20. Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy

Author

Ielasi, Luca, primary, Stefanini, Bernardo, additional, Conti, Fabio, additional, Tonnini, Matteo, additional, Tortora, Raffaella, additional, Magini, Giulia, additional, Sacco, Rodolfo, additional, Pressiani, Tiziana, additional, Trevisani, Franco, additional, Foschi, Francesco Giuseppe, additional, Piscaglia, Fabio, additional, Granito, Alessandro, additional, and Tovoli, Francesco, additional

Published
2024
Full Text
View/download PDF

21. Durvalumab Plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: A Large Real-Life Worldwide Population

Author

Rimini, Margherita, primary, Fornaro, Lorenzo, additional, Rizzato, Mario, additional, Antonuzzo, Lorenzo, additional, Rossari, Federico, additional, Satake, Tomoyuki, additional, Vandeputte, Hanne, additional, Vivaldi, Caterina, additional, Pressiani, Tiziana, additional, Lucchetti, Jessica, additional, Kim, Jin Won, additional, Abidoye, Oluseyi, additional, Rapposelli, Ilario Giovanni, additional, Tamberi, Stefano, additional, Finkelmeier, Fabian, additional, Giordano, Guido, additional, Nichetti, Federico, additional, Chon, Hong Jae, additional, Braconi, Chiara, additional, Pirrone, Chiara, additional, Castet, Florian, additional, Tamburini, Emiliano, additional, Yoo, Changhoon, additional, Parisi, Alessandro, additional, Diana, Anna, additional, Scartozzi, Mario, additional, Prager, Gerald, additional, Avallone, Antonio, additional, Schirripa, Marta, additional, Kim, Il Hwan, additional, Perkhofer, Lukas, additional, Oneda, Ester, additional, Verrico, Monica, additional, Adeva, Jorge, additional, Chan, Stephen L., additional, Spinelli, Gian Paolo, additional, Personeni, Nicola, additional, Garajova, Ingrid, additional, Rodriquenz, Maria Grazia, additional, Leo, Silvana, additional, Salani, Francesca, additional, De Rosa, Antonio, additional, Lavacchi, Daniele, additional, Foti, Silvia, additional, Ikeda, Masafumi, additional, Dekervel, Jeroen, additional, Niger, Monica, additional, Balsano, Rita, additional, Tonini, Giuseppe, additional, Kang, Minsu, additional, Bekaii-Saab, Tanios, additional, Esposito, Luca, additional, Boccaccino, Alessandra, additional, Himmelsbach, Vera, additional, Landriscina, Matteo, additional, Djaballah, Selma Ahcene, additional, Zanuso, Valentina, additional, Masi, Gianluca, additional, Lonardi, Sara, additional, Rimassa, Lorenza, additional, and Casadei Gardini, Andrea, additional

Published
2024
Full Text
View/download PDF

22. A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma

Author

Balcar, Lorenz, primary, Scheiner, Bernhard, additional, Maria Fulgenzi, Claudia Angela, additional, D’Alessio, Antonio, additional, Pomej, Katharina, additional, Roig, Marta Bofill, additional, Meyer, Elias Laurin, additional, Cheon, Jaekyung, additional, Nishida, Naoshi, additional, Lee, Pei-Chang, additional, Wu, Linda, additional, Ang, Celina, additional, Krall, Anja, additional, Saeed, Anwaar, additional, Stefanini, Bernardo, additional, Cammarota, Antonella, additional, Pressiani, Tiziana, additional, Abugabal, Yehia I., additional, Chamseddine, Shadi, additional, Wietharn, Brooke, additional, Parisi, Alessandro, additional, Huang, Yi-Hsiang, additional, Phen, Samuel, additional, Vivaldi, Caterina, additional, Salani, Francesca, additional, Masi, Gianluca, additional, Bettinger, Dominik, additional, Vogel, Arndt, additional, von Felden, Johann, additional, Schulze, Kornelius, additional, Silletta, Marianna, additional, Trauner, Michael, additional, Samson, Adel, additional, Wege, Henning, additional, Piscaglia, Fabio, additional, Galle, Peter R., additional, Stauber, Rudolf, additional, Kudo, Masatoshi, additional, Singal, Amit G., additional, Itani, Aleena, additional, Ulahannan, Susanna V., additional, Parikh, Neehar D., additional, Cortellini, Alessio, additional, Kaseb, Ahmed, additional, Rimassa, Lorenza, additional, Chon, Hong Jae, additional, Pinato, David J., additional, and Pinter, Matthias, additional

Published
2023
Full Text
View/download PDF

23. A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study.

Author

Niger, Monica, Nichetti, Federico, Fornaro, Lorenzo, Pircher, Chiara, Morano, Federica, Palermo, Federica, Rimassa, Lorenza, Pressiani, Tiziana, Berardi, Rossana, Gardini, Andrea Casadei, Sperti, Elisa, Salvatore, Lisa, Melisi, Davide, Bergamo, Francesca, Siena, Salvatore, Mosconi, Stefania, Longarini, Raffaella, Arcangeli, Giuseppina, Corallo, Salvatore, and Delliponti, Laura

Abstract

Background: Biliary tract cancers (BTCs) are rare and lethal cancers, with a 5-year survival inferior to 20%(1–3). The only potential curative treatment is surgical resection. However, despite complex surgical procedures that have a remarkable risk of postoperative morbidity and mortality, the 5-year survival rate after radical surgery (R0) is 20–40% and recurrence rates are up to ~ 75%(4–6). Up to ~ 40% of patients relapse within 12 months after resection, and half of these patient will recur systemically(4–6). There is no standard of care for neoadjuvant chemotherapy (NAC) in resectable BTC, but retrospective reports suggest its potential benefit (7, 8). Methods: PURITY is a no-profit, multicentre, randomized phase II/III trial aimed at evaluating the efficacy of the combination of gemcitabine, cisplatin and nabpaclitaxel (GAP) as neoadjuvant treatment in patients with resectable BTC at high risk for recurrence. Primary objective of this study is to evaluate the efficacy of neoadjuvant GAP followed by surgery as compared to upfront surgery, in terms of 12-month progression-free survival for the phase II part and of progression free survival (PFS) for the phase III study. Key Secondary objectives are event free survival (EFS), relapse-free survival, (RFS), overall survival (OS), R0/R1/R2 resection rate, quality of life (QoL), overall response rate (ORR), resectability. Safety analyses will include toxicity rate and perioperative morbidity and mortality rate. Exploratory studies including Next-Generation Sequencing (NGS) in archival tumor tissues and longitudinal ctDNA analysis are planned to identify potential biomarkers of primary resistance and prognosis. Discussion: Considering the poor prognosis of resected BTC experiencing early tumor recurrence and the negative prognostic impact of R1/R2 resections, PURITY study is based on the rationale that NAC may improve R0 resection rates and ultimately patients’ outcomes. Furthermore, NAC should allow early eradication of microscopic distant metastases, undetectable by imaging but already present at the time of diagnosis and avoid mortality and morbidity associated with resection for patients with rapid progression or worsening general condition during neoadjuvant therapy. The randomized PURITY study will evaluate whether patients affected by BTC at high risk from recurrence benefit from a neoadjuvant therapy with GAP regimen as compared to immediate surgery. Trial registration: PURITY is registered at ClinicalTrials.gov (NCT06037980) and EuCT(2023–503295-25–00). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma

Author

Dharmapuri, Sirish, primary, Özbek, Umut, additional, Jethra, Hiren, additional, Jun, Tomi, additional, Marron, Thomas U, additional, Saeed, Anwaar, additional, Huang, Yi-Hsiang, additional, Muzaffar, Mahvish, additional, Pinter, Matthias, additional, Balcar, Lorenz, additional, Fulgenzi, Claudia, additional, Amara, Suneetha, additional, Weinmann, Arndt, additional, Personeni, Nicola, additional, Scheiner, Bernhard, additional, Pressiani, Tiziana, additional, Navaid, Musharraf, additional, Bengsch, Bertram, additional, Paul, Sonal, additional, Khan, Uqba, additional, Bettinger, Dominik, additional, Nishida, Naoshi, additional, Mohamed, Yehia Ibrahim, additional, Vogel, Arndt, additional, Gampa, Anuhya, additional, Korolewicz, James, additional, Cammarota, Antonella, additional, Kaseb, Ahmed, additional, Galle, Peter R, additional, Pillai, Anjana, additional, Wang, Ying-Hong, additional, Cortellini, Alessio, additional, Kudo, Masatoshi, additional, D’Alessio, Antonio, additional, Rimassa, Lorenza, additional, Pinato, David James, additional, and Ang, Celina, additional

Published
2023
Full Text
View/download PDF

26. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data

Author

Rimini, Margherita, primary, Fornaro, Lorenzo, additional, Lonardi, Sara, additional, Niger, Monica, additional, Lavacchi, Daniele, additional, Pressiani, Tiziana, additional, Lucchetti, Jessica, additional, Giordano, Guido, additional, Pretta, Andrea, additional, Tamburini, Emiliano, additional, Pirrone, Chiara, additional, Rapposelli, Ilario Giovanni, additional, Diana, Anna, additional, Martinelli, Erika, additional, Garajová, Ingrid, additional, Simionato, Francesca, additional, Schirripa, Marta, additional, Formica, Vincenzo, additional, Vivaldi, Caterina, additional, Caliman, Enrico, additional, Rizzato, Mario Domenico, additional, Zanuso, Valentina, additional, Nichetti, Federico, additional, Angotti, Lorenzo, additional, Landriscina, Matteo, additional, Scartozzi, Mario, additional, Ramundo, Matteo, additional, Pastorino, Alessandro, additional, Daniele, Bruno, additional, Cornara, Noemi, additional, Persano, Mara, additional, Gusmaroli, Eleonora, additional, Cerantola, Riccardo, additional, Salani, Francesca, additional, Ratti, Francesca, additional, Aldrighetti, Luca, additional, Cascinu, Stefano, additional, Rimassa, Lorenza, additional, Antonuzzo, Lorenzo, additional, and Casadei‐Gardini, Andrea, additional

Published
2023
Full Text
View/download PDF

27. The ALBI grade refines prognostic prediction in advanced hepatocellular cancer and enables risk stratification for bleeding events following atezolizumab plus bevacizumab

Author

D’Alessio, Antonio, primary, Fulgenzi, Claudia, additional, Scheiner, Bernhard, additional, Korolewicz, James, additional, Cheon, Jaekyung, additional, Nishida, Naoshi, additional, Ang, Celina, additional, Marron, Thomas, additional, Wu, Linda, additional, Saeed, Anwaar, additional, Wietharn, Brooke, additional, Cammarota, Antonella, additional, Pressiani, Tiziana, additional, Pinter, Matthias, additional, Balcar, Lorenz, additional, Huang, Yi-Hsiang, additional, Mehan, Aman, additional, Phen, Samuel, additional, Vivaldi, Caterina, additional, Salani, Francesca, additional, Masi, Gianluca, additional, Bettinger, Dominik, additional, Vogel, Arndt, additional, Schoenlein, Martin, additional, von Felden, Johann, additional, Schulze, Kornelius, additional, Wege, Henning, additional, Samson, Adel, additional, Galle, Peter, additional, Kudo, Masatoshi, additional, Cortellini, Alessio, additional, Singal, Amit, additional, Rimassa, Lorenza, additional, Sharma, Rohini, additional, Chon, Hong Jae, additional, and Pinato, David J., additional

Published
2023
Full Text
View/download PDF

28. Feasibility of systemic anti-cancer therapy as an alternative to best supportive care in patients with advanced HCC and Child-Pugh B liver dysfunction

Author

Fulgenzi, Claudia, primary, D’Alessio, Antonio, additional, Scheiner, Bernhard, additional, Nishida, Naoshi, additional, Ang, Celina, additional, Marron, Thomas, additional, Wu, Linda, additional, Saeed, Anwaar, additional, Wietharn, Brooke, additional, Cammarota, Antonella, additional, Pressiani, Tiziana, additional, Pinter, Matthias, additional, Sharma, Rohini, additional, Cheon, Jaekyung, additional, Huang, Yi-Hsiang, additional, Lee, Pei-Chang, additional, Phen, Samuel, additional, Gampa, Anuhya, additional, Pillai, Anjana, additional, Napolitano, Andrea, additional, Vivaldi, Caterina, additional, Salani, Francesca, additional, Masi, Gianluca, additional, Bettinger, Dominik, additional, Thimme, Robert, additional, Vogel, Arndt, additional, Schoenlein, Martin, additional, Schulze, Kornelius, additional, von Felden, Johann, additional, Wege, Henning, additional, Galle, Peter, additional, Pirisi, Mario, additional, Park, Joong-Won, additional, Kudo, Masatoshi, additional, Rimassa, Lorenza, additional, Singal, Amit, additional, Cortellini, Alessio, additional, Chon, Hong Jae, additional, Ghittoni, Giorgia, additional, Camma, Calogero, additional, Stefanini, Benedetta, additional, Trevisani, Franco, additional, Giannini, Edoardo Giovanni, additional, and Pinato, David J., additional

Published
2023
Full Text
View/download PDF

29. Prognostic impact of metastatic site in patients receiving first-line sorafenib therapy for advanced hepatocellular carcinoma

Author

Lelasi, Luca, primary, Tovoli, Francesco, additional, Tonnini, Matteo, additional, Stefanini, Bernardo, additional, Tortora, Raffaella, additional, Magini, Giulia, additional, Sacco, Rodolfo, additional, Pressiani, Tiziana, additional, Trevisani, Franco, additional, Piscaglia, Fabio, additional, and Granito, Alessandro, additional

Published
2023
Full Text
View/download PDF

32. Figure S4 from Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells

Author

Travelli, Cristina, primary, Consonni, Francesca Maria, primary, Sangaletti, Sabina, primary, Storto, Mariangela, primary, Morlacchi, Sara, primary, Grolla, Ambra A., primary, Galli, Ubaldina, primary, Tron, Gian Cesare, primary, Portararo, Paola, primary, Rimassa, Lorenza, primary, Pressiani, Tiziana, primary, Mazzone, Massimiliano, primary, Trovato, Rosalinda, primary, Ugel, Stefano, primary, Bronte, Vincenzo, primary, Tripodo, Claudio, primary, Colombo, Mario P., primary, Genazzani, Armando A., primary, and Sica, Antonio, primary

Published
2023
Full Text
View/download PDF

33. Data from Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells

Author

Travelli, Cristina, primary, Consonni, Francesca Maria, primary, Sangaletti, Sabina, primary, Storto, Mariangela, primary, Morlacchi, Sara, primary, Grolla, Ambra A., primary, Galli, Ubaldina, primary, Tron, Gian Cesare, primary, Portararo, Paola, primary, Rimassa, Lorenza, primary, Pressiani, Tiziana, primary, Mazzone, Massimiliano, primary, Trovato, Rosalinda, primary, Ugel, Stefano, primary, Bronte, Vincenzo, primary, Tripodo, Claudio, primary, Colombo, Mario P., primary, Genazzani, Armando A., primary, and Sica, Antonio, primary

Published
2023
Full Text
View/download PDF

34. Table S4 from Tumor-Derived Prostaglandin E2 Promotes p50 NF-κB-Dependent Differentiation of Monocytic MDSCs

Author

Porta, Chiara, primary, Consonni, Francesca Maria, primary, Morlacchi, Sara, primary, Sangaletti, Sabina, primary, Bleve, Augusto, primary, Totaro, Maria Grazia, primary, Larghi, Paola, primary, Rimoldi, Monica, primary, Tripodo, Claudio, primary, Strauss, Laura, primary, Banfi, Stefania, primary, Storto, Mariangela, primary, Pressiani, Tiziana, primary, Rimassa, Lorenza, primary, Tartari, Silvia, primary, Ippolito, Alessandro, primary, Doni, Andrea, primary, Soldà, Giulia, primary, Duga, Stefano, primary, Piccolo, Viviana, primary, Ostuni, Renato, primary, Natoli, Gioacchino, primary, Bronte, Vincenzo, primary, Balzac, Fiorella, primary, Turco, Emilia, primary, Hirsch, Emilio, primary, Colombo, Mario P., primary, and Sica, Antonio, primary

Published
2023
Full Text
View/download PDF

35. Supplementary Data from Tumor-Derived Prostaglandin E2 Promotes p50 NF-κB-Dependent Differentiation of Monocytic MDSCs

Author

Porta, Chiara, primary, Consonni, Francesca Maria, primary, Morlacchi, Sara, primary, Sangaletti, Sabina, primary, Bleve, Augusto, primary, Totaro, Maria Grazia, primary, Larghi, Paola, primary, Rimoldi, Monica, primary, Tripodo, Claudio, primary, Strauss, Laura, primary, Banfi, Stefania, primary, Storto, Mariangela, primary, Pressiani, Tiziana, primary, Rimassa, Lorenza, primary, Tartari, Silvia, primary, Ippolito, Alessandro, primary, Doni, Andrea, primary, Soldà, Giulia, primary, Duga, Stefano, primary, Piccolo, Viviana, primary, Ostuni, Renato, primary, Natoli, Gioacchino, primary, Bronte, Vincenzo, primary, Balzac, Fiorella, primary, Turco, Emilia, primary, Hirsch, Emilio, primary, Colombo, Mario P., primary, and Sica, Antonio, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Materials and Methods from Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells

Author

Travelli, Cristina, primary, Consonni, Francesca Maria, primary, Sangaletti, Sabina, primary, Storto, Mariangela, primary, Morlacchi, Sara, primary, Grolla, Ambra A., primary, Galli, Ubaldina, primary, Tron, Gian Cesare, primary, Portararo, Paola, primary, Rimassa, Lorenza, primary, Pressiani, Tiziana, primary, Mazzone, Massimiliano, primary, Trovato, Rosalinda, primary, Ugel, Stefano, primary, Bronte, Vincenzo, primary, Tripodo, Claudio, primary, Colombo, Mario P., primary, Genazzani, Armando A., primary, and Sica, Antonio, primary

Published
2023
Full Text
View/download PDF

37. Data from Tumor-Derived Prostaglandin E2 Promotes p50 NF-κB-Dependent Differentiation of Monocytic MDSCs

Author

Porta, Chiara, primary, Consonni, Francesca Maria, primary, Morlacchi, Sara, primary, Sangaletti, Sabina, primary, Bleve, Augusto, primary, Totaro, Maria Grazia, primary, Larghi, Paola, primary, Rimoldi, Monica, primary, Tripodo, Claudio, primary, Strauss, Laura, primary, Banfi, Stefania, primary, Storto, Mariangela, primary, Pressiani, Tiziana, primary, Rimassa, Lorenza, primary, Tartari, Silvia, primary, Ippolito, Alessandro, primary, Doni, Andrea, primary, Soldà, Giulia, primary, Duga, Stefano, primary, Piccolo, Viviana, primary, Ostuni, Renato, primary, Natoli, Gioacchino, primary, Bronte, Vincenzo, primary, Balzac, Fiorella, primary, Turco, Emilia, primary, Hirsch, Emilio, primary, Colombo, Mario P., primary, and Sica, Antonio, primary

Published
2023
Full Text
View/download PDF

38. Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma

Author

Ielasi, Luca, primary, Tovoli, Francesco, additional, Tonnini, Matteo, additional, Stefanini, Bernardo, additional, Tortora, Raffaella, additional, Magini, Giulia, additional, Sacco, Rodolfo, additional, Pressiani, Tiziana, additional, Trevisani, Franco, additional, Garajová, Ingrid, additional, Piscaglia, Fabio, additional, and Granito, Alessandro, additional

Published
2023
Full Text
View/download PDF

39. IMbrave151: A phase 2, randomized, double-blind, placebo-controlled study of atezolizumab with or without bevacizumab in combination with cisplatin plus gemcitabine in patients with untreated, advanced biliary tract cancer.

Author

El-Khoueiry, Anthony B., primary, Ren, Zhenggang, additional, Chon, Hongjae, additional, Park, Joon Oh, additional, Kim, Jin Won, additional, Pressiani, Tiziana, additional, Li, Daneng, additional, Zhukova, Lyudmila, additional, Chen, Ming-Huang, additional, Hack, Stephen Paul, additional, Wu, Stephanie, additional, Liu, Bo, additional, Wang, Yulei, additional, and Macarulla, Teresa, additional

Published
2023
Full Text
View/download PDF

40. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic biomarkers in unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (atezo-bev).

Author

Wu, Linda, primary, Fulgenzi, Claudia A.M., additional, D'Alessio, Antonio, additional, Chon, Hong Jae, additional, Kudo, Masatoshi, additional, Schönlein, Martin, additional, Felden, Johann von, additional, Wietharn, Brooke, additional, Phen, Samuel, additional, Scheiner, Bernhard, additional, Balcar, Lorenz, additional, Huang, Yi-Hsiang, additional, Pressiani, Tiziana, additional, Masi, Gianluca, additional, Naqash, Abdul Rafeh, additional, Bettinger, Dominik, additional, Vogel, Arndt, additional, Galle, Peter R, additional, Gaillard, Vince, additional, and Ang, Celina, additional

Published
2023
Full Text
View/download PDF

41. Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study

Author

Talbot, Thomas, primary, D'Alessio, Antonio, additional, Pinter, Matthias, additional, Balcar, Lorenz, additional, Scheiner, Bernhard, additional, Marron, Thomas U., additional, Jun, Tomi, additional, Dharmapuri, Sirish, additional, Ang, Celina, additional, Saeed, Anwaar, additional, Hildebrand, Hannah, additional, Muzaffar, Mahvish, additional, Fulgenzi, Claudia A. M., additional, Amara, Suneetha, additional, Naqash, Abdul Rafeh, additional, Gampa, Anuhya, additional, Pillai, Anjana, additional, Wang, Yinghong, additional, Khan, Uqba, additional, Lee, Pei‐Chang, additional, Huang, Yi‐Hsiang, additional, Bengsch, Bertram, additional, Bettinger, Dominik, additional, Mohamed, Yehia I., additional, Kaseb, Ahmed, additional, Pressiani, Tiziana, additional, Personeni, Nicola, additional, Rimassa, Lorenza, additional, Nishida, Naoshi, additional, Kudo, Masatoshi, additional, Weinmann, Arndt, additional, Galle, Peter R., additional, Muhammed, Ambreen, additional, Cortellini, Alessio, additional, Vogel, Arndt, additional, and Pinato, David J., additional

Published
2023
Full Text
View/download PDF

42. Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

Author

Persano, Mara, primary, Rimini, Margherita, additional, Tada, Toshifumi, additional, Suda, Goki, additional, Shimose, Shigeo, additional, Kudo, Masatoshi, additional, Cheon, Jaekyung, additional, Finkelmeier, Fabian, additional, Lim, Ho Yeong, additional, Rimassa, Lorenza, additional, Presa, José, additional, Masi, Gianluca, additional, Yoo, Changhoon, additional, Lonardi, Sara, additional, Tovoli, Francesco, additional, Kumada, Takashi, additional, Sakamoto, Naoya, additional, Iwamoto, Hideki, additional, Aoki, Tomoko, additional, Chon, Hong Jae, additional, Himmelsbach, Vera, additional, Pressiani, Tiziana, additional, Kawaguchi, Takumi, additional, Montes, Margarida, additional, Vivaldi, Caterina, additional, Soldà, Caterina, additional, Piscaglia, Fabio, additional, Hiraoka, Atsushi, additional, Sho, Takuya, additional, Niizeki, Takashi, additional, Nishida, Naoshi, additional, Steup, Christoph, additional, Iavarone, Massimo, additional, Di Costanzo, Giovanni, additional, Marra, Fabio, additional, Scartozzi, Mario, additional, Tamburini, Emiliano, additional, Cabibbo, Giuseppe, additional, Foschi, Francesco Giuseppe, additional, Silletta, Marianna, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Ogawa, Chikara, additional, Nishimura, Takashi, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Tada, Fujimasa, additional, Ohama, Hideko, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Imai, Michitaka, additional, Kosaka, Hisashi, additional, Naganuma, Atsushi, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Kaibori, Masaki, additional, Iijima, Hiroko, additional, Hiasa, Yoichi, additional, Cammarota, Antonella, additional, Burgio, Valentina, additional, Cascinu, Stefano, additional, and Casadei-Gardini, Andrea, additional

Published
2022
Full Text
View/download PDF

43. Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights

Author

Cammarota,Antonella, Zanuso,Valentina, Pressiani,Tiziana, Personeni,Nicola, and Rimassa,Lorenza

Subjects
Journal of Hepatocellular Carcinoma
Abstract

Antonella Cammarota,1,2 Valentina Zanuso,1,2 Tiziana Pressiani,2 Nicola Personeni,1,2,* Lorenza Rimassa1,2,* 1Department of Biomedical Sciences, Humanitas University, Milan, Pieve Emanuele, Italy; 2Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Rozzano, Italy*These authors contributed equally to this workCorrespondence: Lorenza Rimassa, Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Milan, Pieve Emanuele, 20072, Italy, Tel +39 02 82244573, Fax +39 02 82244590, Email lorenza.rimassa@hunimed.euAbstract: Advanced hepatocellular carcinoma (HCC) management has become more complex as novel therapies have been proven effective. After sorafenib, the approval of other multikinase inhibitors (MKIs) and immune checkpoints inhibitors (ICIs) has considerably increased the number of systemic therapies available. Therefore, careful assessment and monitoring of response to systemic treatment are essential to identify surrogate endpoints of overall survival (OS) in clinical trials and reliable tools to gauge treatment benefit in clinical practice. Progression-free survival (PFS) and objective response rate (ORR) are early informative parameters of efficacy that are not influenced by further lines of therapy. However, none of them has shown sufficient surrogacy to be recommended in place of OS in phase 3 trials. With such a wealth of therapeutic options, the prime intent of tumor assessments is no longer limited to identifying progressive disease to spare ineffective treatments to non-responders. Indeed, the early detection of responders could also help tailor treatment sequencing. Tumor assessment relies on the Response Evaluation Criteria for Solid Tumors (RECIST), which are easy to interpret – being based on dimensional principles – but could misread the activity of targeted agents. The HCC-specific modified RECIST (mRECIST), considering both the MKI-induced biological modifications and some of the cirrhosis-induced liver changes, better capture tumor response. Yet, mRECIST could not be considered a standard in advanced HCC. Further prognosticators including progression patterns, baseline and on-treatment liver function deterioration, and baseline alpha-fetoprotein (AFP) levels and AFP response have been extensively evaluated for MKIs. However, limited information is available for patients receiving ICIs and regarding their predictive role. Finally, there is increasing interest in incorporating novel imaging techniques which go beyond sizes and novel serum biomarkers in the advanced HCC framework. Hopefully, multiparametric models grouping dimensional and functional radiological parameters with biochemical markers will most precisely reflect treatment response.Keywords: AFP, HCC, RECIST, mRECIST, surrogate endpoints, systemic therapy

Published
2022

44. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

Author

Wu, Yue Linda, primary, Fulgenzi, Claudia Angela Maria, additional, D’Alessio, Antonio, additional, Cheon, Jaekyung, additional, Nishida, Naoshi, additional, Saeed, Anwaar, additional, Wietharn, Brooke, additional, Cammarota, Antonella, additional, Pressiani, Tiziana, additional, Personeni, Nicola, additional, Pinter, Matthias, additional, Scheiner, Bernhard, additional, Balcar, Lorenz, additional, Huang, Yi-Hsiang, additional, Phen, Samuel, additional, Naqash, Abdul Rafeh, additional, Vivaldi, Caterina, additional, Salani, Francesca, additional, Masi, Gianluca, additional, Bettinger, Dominik, additional, Vogel, Arndt, additional, Schönlein, Martin, additional, von Felden, Johann, additional, Schulze, Kornelius, additional, Wege, Henning, additional, Galle, Peter R., additional, Kudo, Masatoshi, additional, Rimassa, Lorenza, additional, Singal, Amit G., additional, Sharma, Rohini, additional, Cortellini, Alessio, additional, Gaillard, Vincent E., additional, Chon, Hong Jae, additional, Pinato, David J., additional, and Ang, Celina, additional

Published
2022
Full Text
View/download PDF

45. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study

Author

Fulgenzi, Claudia Angela Maria, primary, Cheon, Jaekyung, additional, D'Alessio, Antonio, additional, Nishida, Naoshi, additional, Ang, Celina, additional, Marron, Thomas U., additional, Wu, Linda, additional, Saeed, Anwaar, additional, Wietharn, Brooke, additional, Cammarota, Antonella, additional, Pressiani, Tiziana, additional, Personeni, Nicola, additional, Pinter, Matthias, additional, Scheiner, Bernhard, additional, Balcar, Lorenz, additional, Napolitano, Andrea, additional, Huang, Yi-Hsiang, additional, Phen, Samuel, additional, Naqash, Abdul Rafeh, additional, Vivaldi, Caterina, additional, Salani, Francesca, additional, Masi, Gianluca, additional, Bettinger, Dominik, additional, Vogel, Arndt, additional, Schönlein, Martin, additional, von Felden, Johann, additional, Schulze, Kornelius, additional, Wege, Henning, additional, Galle, Peter R., additional, Kudo, Masatoshi, additional, Rimassa, Lorenza, additional, Singal, Amit G., additional, Sharma, Rohini, additional, Cortellini, Alessio, additional, Gaillard, Vincent E., additional, Chon, Hong Jae, additional, and Pinato, David James, additional

Published
2022
Full Text
View/download PDF

46. Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment

Author

Personeni, Nicola, primary, Pressiani, Tiziana, additional, Zanuso, Valentina, additional, Casadei-Gardini, Andrea, additional, D’Alessio, Antonio, additional, Valgiusti, Martina, additional, Dadduzio, Vincenzo, additional, Bergamo, Francesca, additional, Soldà, Caterina, additional, Rizzato, Mario Domenico, additional, Giordano, Laura, additional, Santoro, Armando, additional, and Rimassa, Lorenza, additional

Published
2022
Full Text
View/download PDF

47. Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma

Author

Vithayathil, Mathew, primary, D'Alessio, Antonio, additional, Fulgenzi, Claudia A. M., additional, Nishida, Naoshi, additional, Schönlein, Martin, additional, von Felden, Johann, additional, Schulze, Kornelius, additional, Wege, Henning, additional, Saeed, Anwaar, additional, Wietharn, Brooke, additional, Hildebrand, Hannah, additional, Wu, Linda, additional, Ang, Celina, additional, Marron, Thomas U., additional, Weinmann, Arndt, additional, Galle, Peter R., additional, Bettinger, Dominik, additional, Bengsch, Bertram, additional, Vogel, Arndt, additional, Balcar, Lorenz, additional, Scheiner, Bernhard, additional, Lee, Pei‐Chang, additional, Huang, Yi‐Hsiang, additional, Amara, Suneetha, additional, Muzaffar, Mahvish, additional, Naqash, Abdul Rafeh, additional, Cammarota, Antonella, additional, Personeni, Nicola, additional, Pressiani, Tiziana, additional, Pinter, Matthias, additional, Cortellini, Alessio, additional, Kudo, Masatoshi, additional, Rimassa, Lorenza, additional, Pinato, David J., additional, and Sharma, Rohini, additional

Published
2022
Full Text
View/download PDF

48. Multidisciplinary Tumor Board in the Management of Patients with Colorectal Liver Metastases: A Single-Center Review of 847 Patients

Author

Milana, Flavio, primary, Famularo, Simone, additional, Luberto, Antonio, additional, Rimassa, Lorenza, additional, Scorsetti, Marta, additional, Comito, Tiziana, additional, Pressiani, Tiziana, additional, Franzese, Ciro, additional, Poretti, Dario, additional, Di Tommaso, Luca, additional, Personeni, Nicola, additional, Rodari, Marcello, additional, Pedicini, Vittorio, additional, Donadon, Matteo, additional, and Torzilli, Guido, additional

Published
2022
Full Text
View/download PDF

49. Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential Treatments

Author

Tovoli, Francesco, primary, Pallotta, Dante Pio, additional, Sansone, Vito, additional, Iavarone, Massimo, additional, De Giorgio, Massimo, additional, Ielasi, Luca, additional, Di Costanzo, Giovan Giuseppe, additional, Giuffrida, Paolo, additional, Sacco, Rodolfo, additional, Pressiani, Tiziana, additional, Di Donato, Maria Francesca, additional, Trevisani, Franco, additional, Fagiuoli, Stefano, additional, Piscaglia, Fabio, additional, and Granito, Alessandro, additional

Published
2022
Full Text
View/download PDF

50. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

Author

Vithayathil, Mathew, primary, D’Alessio, Antonio, additional, Weinmann, Arndt, additional, Galle, Peter, additional, Maria Fulgenzi, Claudia Angela, additional, Fessas, Petros, additional, Bettinger, Dominik, additional, Bengsch, Bertram, additional, Vogel, Arndt, additional, Balcar, Lorenz, additional, Scheiner, Bernhard, additional, Muzaffar, Mahvish, additional, Amara, Suneetha, additional, Muhammed, Ambreen, additional, Naqash, Abdul Rafeh, additional, Personeni, Nicola, additional, Pressiani, Tiziana, additional, Cammarota, Antonella, additional, Pinter, Matthias, additional, Cortellini, Alessio, additional, Rimassa, Lorenza, additional, Pinato, David J., additional, and Sharma, Rohini, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results